Addressing the issues surrounding pharmacy benefit managers and the Inflation Reduction Act (IRA) would help to curb health care costs for patients, said John M. O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council.
John Michael O'Brien, PharmD, MPH, president and CEO of the National Pharmaceutical Council (NPC), discussed how the current administration could focus on the Inflation Reduction Act, pharmacy benefit managers (PBMs), and the 340B program to help patients with the rising cost of health care.
This transcript was lightly edited for clarity; captions were auto-generated.
Transcript
What do you think are the most pressing questions around drug access that will be addressed in the policy decisions of this administration and Congress?
One of the things that I love most about being in policy and research, as opposed to politics, is that the evidence we generate with our research is useful to policy makers, regardless of who’s in office. Here’s what we know right now: President [Donald] Trump just released an executive order that takes on issues that we've been focused on at NPC for some time, like investigating and fixing the pill penalty that exists within the Inflation Reduction Act drug price negotiation program, taking a good hard look at the 340B program and proposing some reforms to help patients, taking a look at the role of middlemen and their business practices, and otherwise improving transparency within the value chain.
Now, our research and the work of others has identified that the Inflation Reduction Act will delay launches, reduce the number of subsequent indications, and have a chilling effect on postapproval outcomes research. There are also a number of unanswered questions about whether or not patients will benefit from the Inflation Reduction Act’s effectuation, if you will, at the pharmacy counter. There’s uncertainty still about whether or how this law will actually disincentivize the development of small-molecule drugs or drugs with additional orphan designations to help patients living with rare diseases.
On the 340B side, our research has identified that 340B is not a victimless crime that only takes money from pharmaceutical manufacturers. It’s costing employers, it’s costing states, and that’s ultimately costing patients. Our research found that costs for self-insured employers are actually going up about $5 billion to $6 billion a year because of this program, and research from the National Alliance of Healthcare Purchaser [Coalitions] looked outside drug costs and found that a 7.5% higher claims cost is actually costing employers a lot more in health care premiums.
And when we think about pharmacy benefit managers, their business practices are hurting patients. They’re not transparent, and these middlemen are keeping about half of what we call “drug spending” in the United States. I do hope that policy makers take a good look at the evidence, fix the perverse incentives caused by the Inflation Reduction Act, address the way that the last administration interpreted the orphan drug exemption, pass meaningful PBM reform, and help restore the 340B program to its original intent and stop the explosive growth that’s increasing health care costs for self-insured employers.
But most importantly, when it comes to policy, we need to remember that good policy making begins with good evidence, and that’s something that we’re focused on and going to continue to do here at the NPC.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More